Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight

DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
• The leading Myelodysplastic Syndrome Companies working in the market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Promising Myelodysplastic Syndrome Therapies in the various stages of development include Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.
• In April 2025, Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announced positive topline results of the BEXMAB trial, which shows a high overall response rate (ORR) among both frontline as well as relapsed/refractory (r/r) HR MDS patients treated with a combination of bexmarilimab and azacitidine.
• In January 2025, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the successful completion of the regulatory review process for GRAFAPEXTM (treosulfan) for injection with the US Food and Drug Administration and, in addition, to announce preliminary estimates of the company's operating and financial results for the company's third fiscal quarter ended December 31, 2024 (which remain subject to completion of Medexus's financial closing procedures). All dollar amounts in this news release are in US dollars unless specified otherwise.
• May 2024:- Bristol-Myers Squibb- The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
• May 2024-Washington University School of Medicine- This phase I trial studies the side effects and the best dose of vosaroxin when given together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Request a sample and discover the recent advances in Myelodysplastic Syndrome treatment drugs @ Myelodysplastic Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelodysplastic Syndrome Overview
Myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized by ineffective blood cell production (dysplasia) in the bone marrow, leading to cytopenias and an increased risk of progression to acute myeloid leukemia (AML). Myelodysplastic syndromes primarily affects older adults, with a median age of diagnosis around 70 years, and is often associated with genetic mutations, environmental exposures (e.g., radiation, chemotherapy, or toxins), and unknown factors.
Symptoms of Myelodysplastic syndromes are related to the type and severity of cytopenias. Anemia is the most common, causing fatigue, weakness, and pallor. Thrombocytopenia can result in easy bruising or bleeding, while neutropenia increases susceptibility to infections. Diagnosis typically involves blood tests showing low cell counts, bone marrow biopsy, and cytogenetic analysis to detect chromosomal abnormalities or genetic mutations.
Myelodysplastic syndromes is classified by the World Health Organization (WHO) based on specific morphological, genetic, and clinical features. Treatment varies depending on risk stratification (low or high risk), patient age, and comorbidities. Options include supportive care (blood transfusions, growth factors), hypomethylating agents (azacitidine, decitabine), immunosuppressive therapy, or allogeneic stem cell transplantation for eligible patients.
Advances in targeted therapies and molecular research continue to improve outcomes, emphasizing personalized approaches for managing this complex condition.

Myelodysplastic Syndrome Emerging Drugs Profile
• MBG453: Novartis
• Tamibarotene: Syros Pharmaceuticals
• CA-4948: Curis
• RVU120: Ryvu Therapeutics

Find out more about Myelodysplastic Syndrome treatment drugs @ Drugs for Myelodysplastic Syndrome Treatment- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelodysplastic Syndrome Therapeutics Assessment
There are approx. 120+ key Myelodysplastic Syndrome companies which are developing the therapies for Myelodysplastic Syndrome. The Myelodysplastic Syndrome companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

DelveInsight's Myelodysplastic Syndrome report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Myelodysplastic Syndrome pipeline therapies @ Myelodysplastic Syndrome Clinical Trials- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Myelodysplastic Syndrome Companies
Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.

Dive deep into rich insights for new drugs for Myelodysplastic Syndrome Treatment, visit @ Myelodysplastic Syndrome Drugs- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Myelodysplastic Syndrome Pipeline Report
• Coverage- Global
• Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myelodysplastic Syndrome Companies- Novartis (SWX: NOVN), Syros Pharmaceuticals (NASDAQ: SYRS), Curis (NASDAQ: CRIS), Ryvu Therapeutics (WSE: RVU), Chia Tai Tianqing Pharmaceutical Group (HKEX: 1177) (part of Sino Biopharmaceutical Limited), Amgen (NASDAQ: AMGN), Sanofi (EPA: SAN), Forma Therapeutics (formerly NASDAQ: FMTX, acquired by Novo Nordisk), Agios Pharmaceuticals (NASDAQ: AGIO), AbbVie (NYSE: ABBV), Daiichi Sankyo Company (TYO: 4568), Geron Corporation (NASDAQ: GERN), Astex Pharmaceuticals (acquired, subsidiary of Otsuka Holdings, TYO: 4578), Jazz Pharmaceuticals (NASDAQ: JAZZ), Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062), BeiGene (NASDAQ: BGNE, HKEX: 6160, SHA: 688235), Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals (OTC: BLCM), and others.
• Myelodysplastic Syndrome Therapies- Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.

For further information on the Myelodysplastic Syndrome Pipeline Therapeutics, reach out @ Myelodysplastic Syndrome Treatment Drugs- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.